Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ALDARA (imiquimod)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ALDARA (imiquimod)

Medicine - Posted on Nov 08 2016 - Updated on Jun 12 2019
Active substance (DCI)
  • imiquimod
history (6)
  • 10/19/16

    ALDARA (imiquimod)

    Avis défavorable au maintien du remboursement dans l'indication des petits carcinomes baso-cellulaires superficiels sans con...
    icône flèche
  • 11/4/15

    ALDARA (imiquimod)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 3/10/10

    ALDARA

    ALDARA
    icône flèche
  • 11/26/08

    ALDARA

    DERMATOLOGIE – Nouvelle indication ALDARA 5 % (imiquimod), immunomodulateur Un moyen thérapeutique supplémentaire utile sans...
    CAV :
    54321
    icône flèche
  • 4/13/05

    ALDARA (imiquimod)

    ALDARA (imiquimod)
    icône flèche
  • 3/16/05

    ALDARA (imiquimod)

    ALDARA (imiquimod)
    icône flèche
Technical information
ATC code
  • D06BB10
Manufacturer
MEDA PHARMA
Presentation

ALDARA 5 %, crème (code CIS : 66916232) - 12 sachet(s) polyester aluminium de 250 mg - Code CIP : 3400934920448

All our publications
    Drug therapy Female genital diseases Male genital diseases Skin and connective tissue cancers Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
ZgQJe1EQVAQGxP5h